Hellmann MD, et al. Efficacy/Safety of Entinostat (ENT) and Pembrolizumab (PEMBRO) in NSCLC Patients Previously Treated with Anti-PD-(L)1 Therapy. IASLC 2018, abstract OA05.01.
Grote globale verschillen in implementatie van hypofractionering bij radiotherapie
nov 2018 | Borstkanker, Radiotherapie, Uro-oncologie